Journey Medical CFO granted stock, options
Journey Medical Corp CFO Joseph Benesch received new equity awards as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Journey Medical Corp CFO Joseph Benesch received new equity awards as part of his compensation. On April 22, 2026, he was granted 28,907 restricted stock units that vest in three annual installments from April 2027 through April 2029. He also received 41,860 stock options with an exercise price of $5.04 per share, vesting annually over the same three-year period and expiring in 2036. After these awards, he directly holds 261,371 shares of common stock, and has 41,860 options outstanding.
Insider Trade Summary
Grant/Award: 70,767 shares
Grant/Award
2 txns
Insider
Benesch Joseph
Role
CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 41,860 | $0.00 | $0.00 |
| Grant/Award | Common Stock, $0.0001 par value | 28,907 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 41,860 contracts (Direct);
Common Stock, $0.0001 par value — 261,371 shares (Direct)
Footnotes (3)
- F1. On April 22, 2026, the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 9,636 shares on April 22, 2027, 9,636 shares on April 22, 2028 and 9,635 shares on April 22, 2029.
- F2. Includes restricted stock units, which vest over various time periods.
- F3. On April 22, 2026, the reporting person was granted 41,860 stock options pursuant to the Issuer's 2015 Stock Plan, as amended, that will vest in accordance with the following schedule: 13,953 shares on April 22, 2027, 13,953 shares on April 22, 2028 and 13,954 shares on April 22, 2029.
Key Figures
RSU grant: 28,907 units
Option grant size: 41,860 options
Option exercise price: $5.04 per share
+5 more
8 metrics
RSU grant
28,907 units
Restricted stock units granted on April 22, 2026
Option grant size
41,860 options
Stock options granted on April 22, 2026
Option exercise price
$5.04 per share
Strike price for stock options
Options expiration
April 22, 2036
Expiration date of stock options
Shares held after grant
261,371 shares
Common stock directly owned after transactions
Options held after grant
41,860 options
Total options directly owned after transactions
First RSU vesting
9,636 units
Vest on April 22, 2027
Final RSU vesting
9,635 units
Vest on April 22, 2029
Key Terms
restricted stock units, Stock Option (Right to Buy), exercise price, 2015 Stock Plan, +1 more
5 terms
restricted stock units financial
"the reporting person was granted 28,907 restricted stock units pursuant to the Issuer's 2015 Stock Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 5.0400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
2015 Stock Plan financial
"pursuant to the Issuer's 2015 Stock Plan, as amended"
expiration date financial
"expiration_date: 2036-04-22T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Journey Medical (DERM) CFO Joseph Benesch receive in this Form 4?
CFO Joseph Benesch received 28,907 restricted stock units and 41,860 stock options. These equity awards are compensation grants that give him future rights to Journey Medical common shares if vesting conditions are satisfied over several years.
How do the new restricted stock units for Journey Medical (DERM) CFO vest?
The 28,907 restricted stock units vest in three annual tranches: 9,636 units on April 22, 2027, another 9,636 on April 22, 2028, and 9,635 on April 22, 2029. Each vesting date delivers actual Journey Medical shares if conditions are met.
What are the terms of the stock options granted to Journey Medical (DERM) CFO?
The CFO received 41,860 stock options with a $5.04 exercise price. These options vest in three equal annual installments from April 22, 2027 through April 22, 2029, and expire on April 22, 2036 if they are not exercised into common shares.
Is the Journey Medical (DERM) Form 4 a stock purchase or a compensation grant?
This Form 4 reflects compensation grants, not market purchases or sales. The transactions are coded “A” for awards, granting restricted stock units and stock options at no cash cost to the CFO, subject to multi-year vesting schedules under the company’s stock plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates